1256289-67-4Relevant academic research and scientific papers
Rational design, synthesis, and SAR of a novel thiazolopyrimidinone series of selective PI3K-beta inhibitors
Lin, Hong,Schulz, Mark J.,Xie, Ren,Zeng, Jin,Luengo, Juan I.,Squire, Michael D.,Tedesco, Rosanna,Qu, Junya,Erhard, Karl,MacK, James F.,Raha, Kaushik,Plant, Ramona,Rominger, Cynthia M.,Ariazi, Jennifer L.,Sherk, Christian S.,Schaber, Michael D.,McSurdy-Freed, Jeanelle,Spengler, Michael D.,Davis, Charles B.,Hardwicke, Mary Ann,Rivero, Ralph A.
, p. 524 - 529 (2012/10/23)
A novel thiazolopyrimidinone series of PI3K-beta selective inhibitors has been identified. This chemotype has provided an excellent tool compound, 18, that showed potent growth inhibition in the PTEN-deficient breast cancer cell line MDA-MB-468 under anchorage-independent conditions, and it also demonstrated pharmacodynamic effects and efficacy in a PTEN-deficient prostate cancer PC-3 xenograft mouse model.
THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS
-
Page/Page column 63-64, (2010/12/18)
This invention relates to the use of thiazolopyrimidinone derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3' OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ
